A Dimeric Mutant of Human Pancreatic Ribonuclease with Selective Cytotoxicity Toward Malignant Cells
Overview
Authors
Affiliations
Monomeric human pancreatic RNase, devoid of any biological activity other than its RNA degrading ability, was engineered into a dimeric protein with a cytotoxic action on mouse and human tumor cells, but lacking any appreciable toxicity on mouse and human normal cells. This dimeric variant of human pancreas RNase selectively sensitizes to apoptotic death cells derived from a human thyroid tumor. Because of its selectivity for tumor cells, and because of its human origin, this protein represents a potentially very attractive, novel tool for anticancer therapy.
Biological Activities of Secretory RNases: Focus on Their Oligomerization to Design Antitumor Drugs.
Gotte G, Menegazzi M Front Immunol. 2019; 10:2626.
PMID: 31849926 PMC: 6901985. DOI: 10.3389/fimmu.2019.02626.
Mironova N, Vlassov V Front Pharmacol. 2019; 10:1019.
PMID: 31572192 PMC: 6753386. DOI: 10.3389/fphar.2019.01019.
Small Molecule-Induced Domain Swapping as a Mechanism for Controlling Protein Function and Assembly.
Karchin J, Ha J, Namitz K, Cosgrove M, Loh S Sci Rep. 2017; 7:44388.
PMID: 28287617 PMC: 5347425. DOI: 10.1038/srep44388.
Dan X, Liu W, Wong J, Ng T Front Pharmacol. 2016; 7:217.
PMID: 27504094 PMC: 4958627. DOI: 10.3389/fphar.2016.00217.
Vert A, Castro J, Ribo M, Benito A, Vilanova M Oncotarget. 2016; 7(14):18309-24.
PMID: 26918450 PMC: 4951290. DOI: 10.18632/oncotarget.7579.